Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces the risk of being delisted due to significant violations, including failure to disclose the actual controller and inflating revenue, costs, and profits, leading to stock suspension on November 26, 2025 [1][5]. Group 1: Violations and Penalties - Jiangsu Wuzhong and related personnel failed to disclose the actual controller and falsely reported financial data from 2018 to 2023, inflating revenue by a total of 4.95 billion, 4.69 billion, 4.31 billion, and 3.77 billion respectively, which accounted for 26.46%, 26.39%, 21.26%, and 16.82% of reported revenue for those years [2][3]. - The company was fined a total of 30.5 million yuan, with the actual controller, Qian Qunshan, receiving a 10-year ban from the securities market due to severe violations [4]. Group 2: Financial Performance and Business Transition - Jiangsu Wuzhong has experienced a decline in performance since 2018, with a net profit loss of 286 million yuan in that year, and has been in a loss state for most years since, except for 2019 and 2021 [7]. - The company entered the medical aesthetics sector in 2021, which initially improved its financial performance, with a net profit of 70.48 million yuan in 2024, despite a 28.64% drop in overall revenue [8]. - However, in the first quarter of the current year, the company reported a net loss of 70.32 million yuan, indicating a reversal in its financial recovery [8].

Core Viewpoint - *ST Suwu, after 26 years of listing, is facing forced delisting due to four consecutive years of financial fraud and significant fund misappropriation, potentially becoming the ninth major illegal delisting company by 2025 [1][3][17] Financial Fraud - From 2020 to 2023, *ST Suwu engaged in continuous financial fraud, with inflated profits peaking at 51.65%. The total inflated profit amounted to 0.76 billion, with inflated operating income and costs reaching 1.772 billion and 1.695 billion respectively [6][17] - The proportion of inflated profits was notably high, with over 25% of profits being fraudulent from 2021 to 2023, and the highest in 2021 at 51.65% [6][17] Fund Misappropriation - *ST Suwu has experienced severe fund misappropriation, with the highest misappropriation rate reaching 96.09%. The non-operating fund misappropriation from 2020 to 2023 was recorded at 1.27 billion, 1.393 billion, 1.543 billion, and 1.693 billion respectively, representing 6.88%, 74.20%, 84.60%, and 96.09% of the net assets [7][8][17] - As of 2024, there remains 769 million in misappropriated funds that have not been returned [8] Disclosure Issues - The actual controller of *ST Suwu changed in February 2018, but this was not disclosed in annual reports from 2018 to 2023 [10][11] - The company has faced multiple penalties and has been under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations [3][13] Regulatory Environment - The new delisting regulations effective from January 1, 2025, have tightened the criteria for major illegal delisting, particularly focusing on financial fraud [17][18] - Since the tightening of regulations, eight companies have already faced delisting due to financial fraud, with *ST Suwu likely to follow [1][18] Investor Protection - In response to the crackdown on financial fraud, investor protection measures are being enhanced, including civil compensation lawsuits initiated by investors against *ST Suwu [19]

Core Viewpoint - *ST Suwu (600200) is facing mandatory delisting due to four consecutive years of financial fraud and significant fund misappropriation, potentially becoming the ninth major company to be delisted for serious violations by 2025 [1][2][3] Financial Fraud - From 2020 to 2023, *ST Suwu engaged in continuous financial fraud, with profit inflation peaking at 51.65% in 2021. The total inflated profit amounted to 0.76 billion yuan, with inflated operating income and costs reaching 1.772 billion yuan and 1.695 billion yuan respectively [6][7] - The proportion of inflated profits was notably high, with over 25% of profits being fraudulent from 2021 to 2023, and 2021 seeing the highest inflation rate at 51.65% [6] Fund Misappropriation - *ST Suwu has experienced severe fund misappropriation, with the highest rate reaching 96.09% of its net assets by 2023. The non-operational fund occupation by related parties increased significantly from 1.27 billion yuan in 2020 to 16.93 billion yuan in 2023 [7][8] - By 2023, over 70% of *ST Suwu's net assets had been "emptied," with 7.69 billion yuan of misappropriated funds still outstanding [8] Disclosure Issues - The company failed to disclose a change in its actual controller for six years, which occurred in February 2018, leading to significant penalties [9] - The company and its main responsible individuals were fined a total of 30.5 million yuan, with the chairman facing the highest penalty of 15 million yuan and a 10-year market ban [9] Regulatory Environment - The new delisting regulations effective from January 1, 2025, have tightened the standards for mandatory delisting, particularly focusing on financial fraud [2][14] - Since the tightening of regulations, eight companies have already faced delisting procedures due to serious violations, indicating a trend towards stricter enforcement [14] Company Background - *ST Suwu, established in 1994 and listed in 1999, has struggled with poor performance in its core pharmaceutical and real estate businesses, leading to continuous losses from 2018 to 2023 [11] - Despite a brief recovery in 2024 due to a new product line, the company reported a net loss of 0.74 billion yuan in the first quarter of 2025 [11] Legal and Investor Protection - Following the investigation into *ST Suwu, investors have begun filing civil compensation lawsuits, supported by new measures for investor protection [15] - The introduction of advance compensation and commitments from administrative enforcement parties aims to enhance investor rights and recovery options [15]